The Great Debate: Metabolic Surgery vs. Glucagon-Like Peptide-1 Receptor Agonists in Managing Patients with Obesity and its Related Comorbid Medical Illnesses.

Andrew A Wheeler, Norbert Richardson, Joshua Landreneau

Abstract readReview

In one paragraph

Review in Missouri medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andrew A WheelerAssociate Professor, Department of Surgery, University of Missouri School of Medicine, Department of Surgery, Columbia, Missouri, USA.

Norbert RichardsonAssociate Professor, Department of Surgery, University of Missouri School of Medicine, Department of Surgery, Columbia, Missouri, USA.

Joshua LandreneauAssistant Professor, Department of Surgery, University of Missouri School of Medicine, Department of Surgery, Columbia, Missouri, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity as a chronic disease continues to increase in prevalence despite continual advancements in surgical and medical therapy. Bariatric surgery has been the gold-standard for effective treatment of obesity and its related diseases for multiple decades. However, with the continual introduction of newer and more effective glucagon-like peptide one receptor agonists, the most effective non-surgical therapy to date, the debate has begun about which therapy is more effective in treating patients suffering from chronic obesity. As data continues to emerge, further consideration must be given regarding the use of these modalities as monotherapy or as combination therapy for treating obesity. We will provide arguments for each therapy and make a further argument for multimodal therapy to treat the challenging disease of obesity.

Indexed as

Bariatric SurgeryGlucagon-Like Peptide-1 Receptor AgonistsObesityComorbidityHumansWeight LossGlucagon-Like Peptide-1 Receptor AgonistsBariatric surgerycombination therapyglucacon-like peptide one receptor agonist (GLP-1 RA)medical weight loss

Identifiers

PMID42891416

PMCPMC13674934

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.